Genetic Analysis AS (GA) reports first commercial sales of the enhanced GA-map® Dysbiosis Test version 2
OSLO, NORWAY – 27th January 2022: Today, GA achieved another important milestone; first commercial sales of the new and enhanced version of the GA-map® Dysbiosis Test to the US market….
Genetic Analysis AS (GEAN): Mandatory notification of trade – Primary Insiders
OSLO, NORWAY – 13 January 2022: Genetic Analysis AS (“GA” or “the Company”) announce that members of the management have bought GEAN-shares. Ronny Hermansen, CEO in Genetic Analysis AS, has…
Genetic Analysis AS and Thalys Medical Technology Group enter Microbiome Laboratory Developed Test (LDT) agreement for the Chinese market
OSLO, NORWAY/SHANGHAI, CHINA – 13. January 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Thalys Medical Technology Group Corporation (“Thalys”) announces today that the parties have entered a Laboratory…
Genetic Analysis summarizes a successful year
OSLO, NORWAY – 21 December 2021: 2021 has been an eventful year for Genetic Analysis (“GA” or “the Company”), in which the Company made strong progress in a market that…
Interim report January – September 2021
(Oslo, 9 November 2021) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2021. The interim report is available…
Genetic Analysis awarded important US patent covering a companion diagnostic method for optimising IBS interventions
OSLO, NORWAY – 28 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces the award of an important patent (US20200400666) by the United States Patent and…
Genetic Analysis enters a Service Agreement with Eurofins ADME BIOANALYSES – The first CRO to offer the GA-map® Microbiome test
OSLO, NORWAY – 19 October 2021: Molecular diagnostics specialist, Genetic Analysis AS (GA) today announced a Service Agreement with Eurofins ADME BIOANALYSES, a Contract Research Organisation (CRO) providing diverse services…
Genetic Analysis receives important patent allowance in China
OSLO, NORWAY – 14 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has been awarded an important patent (CN107430644A) by the China…
Microbiome Dx Genetic Analysis raises USD 6.8 M in IPO
Microbiome Dx Genetic Analysis raises USD 6.8 M in IPO Closes up 50 % on first two days of trading as EU and US commercialisation drive of GA-map® platform begins…
Genetic Analysis AS (GEAN): First day of trading in Genetic Analysis shares and warrants on Spotlight Stock Market
OSLO, NORWAY – 1 October 2021: First day of trading in Genetic Analysis AS (“GA” or “the Company”) shares and warrants on Spotlight Stock Market (“Spotlight”) begins today. The Company’s…
Genetic Analysis AS (GEAN): Disclosure of Large Shareholding
OSLO, NORWAY – 24 September 2021: Reference is made to the press release on 15 September 2021 from Genetic Analysis AS (“the Company”, XSAT ticker: GEAN) regarding a public placement…
Genetic Analysis AS (GEAN): Registration of share capital increase
OSLO, NORWAY – 24 September 2021: Reference is made to the press release on 20 September 2021 from Genetic Analysis AS (“the Company”, XSAT ticker: GEAN) regarding the minutes from…
Genetic Analysis AS (GEAN): Minutes from the Extraordinary General Meeting
OSLO, NORWAY – 20 September 2021: On 20 September 2021, an extraordinary general meeting in Genetic Analysis AS (“GA” or “the Company”) took place at 14.00 CET. Today’s extraordinary general…
Genetic Analysis AS (GEAN): Mandatory notification of trade
OSLO, NORWAY – 15 September 2021: Genetic Analysis AS (“GA” or “the Company”) announce that members of the Board and management have been allocated GEAN-shares and warrants of series TO…
Genetic Analysis AS (GEAN) : IPO prior to listing was significantly oversubscribed
OSLO, NORWAY – 15 September 2021: On 13 September 2021, the subscription period in Genetic Analysis AS (“GA” or “the Company”) issue of units (“the IPO”) prior to the planned…